fda semaglutide shortage lawsuit free to pursue compounders after latest court ruling US judge upholds FDA's removal

Fit women across all BMIs had a lower mortality and cardiovascular event rate than unfit women of all BMIs

Single, well-defined reaction product for each amino acid

Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis

Weight loss results: Key findings: At the highest dose (12 mg), participants lost an average of 24.2% of body weight Weight loss had not plateaued at 48 weeksparticipants were still losing 72% of participants with prediabetes reverted to normal blood sugar Improvements in blood pressure, lipids, and other metabolic markers Context: These results exceed those seen with semaglutide (~15-17% in trials) and are comparable to or slightly better than tirzepatide (~21% at highest doses)

Liu Y, Yu Z, Zhao S, Cheng L, Man Y, Gao X, et al

Intensified radiance + maintenance reinforcement